Navigation Links
Medarex to Present at the Needham Cancer Therapeutics Conference
Date:3/18/2009

PRINCETON, N.J., March 18 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it is scheduled to present at the Needham & Company Cancer Therapeutics: Today & Tomorrow Conference at 11:20 a.m. Eastern Time on Thursday, March 26, 2009. The event will be webcast live and will be available in the Investor Relations section of the Medarex website at www.medarex.com. An archived edition of the presentation will be available following the event.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently in Phase 3 clinical trials, the subject of regulatory applications for marketing authorization or approved in Canada and Europe. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
2. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
3. Medarex to Present at the 27th Annual J.P. Morgan Healthcare Conference
4. Medarex to Present at the RBC Capital Markets Healthcare Conference
5. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
6. Medarex Announces 2008 Third Quarter Financial Results
7. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
8. Medarex to Present at the UBS Global Life Sciences Conference
9. Medarex to Present at the Thomas Weisel Partners Healthcare Conference
10. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
11. Medarex Announces July 10 Live Webcast of R&D Day Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity ... intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining centers at ... result of a collaboration among several companies with expertise in toolholding, cutting tools, ...
(Date:6/23/2016)... India , June 23, 2016 ... media market research report to its pharmaceuticals section ... profiles, product details and much more. ... spread across 151 pages, profiling 15 companies and ... available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
Breaking Biology Technology:
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
Breaking Biology News(10 mins):